SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violat...
May 27 2016 - 2:47PM
Business Wire
Levi & Korsinsky announces it has commenced an investigation
of Jazz Pharmaceuticals plc (“Jazz Pharmaceuticals” or the
“Company”) (NASDAQ:JAZZ) concerning possible violations of federal
securities laws.
On May 6, 2016, Jazz Pharmaceuticals acknowledged receipt of a
subpoena from the U.S. Attorney’s Office for the District of
Massachusetts in May 2016. According to the Company, the subpoena
requested documents related to the Company’s “support of 501(c)(3)
organizations that provide financial assistance to Medicare
patients, and, for Xyrem, documents concerning our provision of
financial assistance to Medicare patients.” Then on May 27, 2016,
Bloomberg reported that Jazz Pharmaceuticals is one of three major
drugmakers to disclose receipt of a subpoena as part of this
expanding federal investigation. To obtain additional information
about the investigation, go to:
http://zlk.9nl.com/jazz-pharmaceuticals-jazz
or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation involving financial
fraud, and have recovered hundreds of millions of dollars for
aggrieved shareholders. Attorney advertising. Prior results do not
guarantee similar outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160527005775/en/
Levi & Korsinsky, LLPEduard Korsinsky, Esq.,
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Apr 2023 to Apr 2024